Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.

Phanthaboon Wangpatharawanit, Somnuek Sungkanuparph

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017;63(6):818-20

PMID: 27402817

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.

Address: Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

DOI: 10.1093/cid/ciw395

Link outs

Free resources

Medical:

https://medlineplus.gov/hivmedicines.html

Other Literature Sources:

https://scite.ai/reports/27402817

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Atazanavir Sulfate, Atorvastatin, Cholesterol, Female, HIV Infections, Humans, Hypercholesterolemia, Lipoproteins, LDL, Lopinavir, Male, Middle Aged, Ritonavir